BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 21479234)

  • 21. Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group.
    Ono T; Sasajima T; Shimizu H; Natsumeda M; Kanamori M; Asano K; Beppu T; Matsuda K; Ichikawa M; Fujii Y; Ohkuma H; Ogasawara K; Sonoda Y; Saito K; Nobusawa S; Nakazato Y; Kitanaka C; Kayama T; Tominaga T;
    Neurol Med Chir (Tokyo); 2020 Nov; 60(11):543-552. PubMed ID: 33071274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
    Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
    J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular features of pleomorphic xanthoastrocytoma.
    Zou H; Duan Y; Wei D; Zhang Y; Dai J; Li J; Li X; Zhou J; Liu Z; Jin Z; Zhang Z; Yu Y; Hu Z
    Hum Pathol; 2019 Apr; 86():38-48. PubMed ID: 30496796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
    Kim SH; Hwang K; Lee KS; Choe G; Kim CY
    World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
    Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
    Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebellar pleomorphic xanthoastrocytoma in the setting of neurofibromatosis type-I: Does it portend a different prognosis? A case report and systematic review.
    Mathkour M; Banerjee S; Werner C; Hanna J; Abou-Al-Shaar H; Dindial R; Scullen T; Boehm L; Tubbs RS; Ware ML
    Clin Neurol Neurosurg; 2021 Jan; 200():106346. PubMed ID: 33160715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?
    Vaubel R; Zschernack V; Tran QT; Jenkins S; Caron A; Milosevic D; Smadbeck J; Vasmatzis G; Kandels D; Gnekow A; Kramm C; Jenkins R; Kipp BR; Rodriguez FJ; Orr BA; Pietsch T; Giannini C
    Brain Pathol; 2021 Jan; 31(1):20-32. PubMed ID: 32619305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation.
    Hong CS; Wang JL; Dornbos D; Joehlin-Price A; Elder JB
    World Neurosurg; 2017 Feb; 98():871.e9-871.e15. PubMed ID: 27956254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
    Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
    Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
    Chappé C; Padovani L; Scavarda D; Forest F; Nanni-Metellus I; Loundou A; Mercurio S; Fina F; Lena G; Colin C; Figarella-Branger D
    Brain Pathol; 2013 Sep; 23(5):574-83. PubMed ID: 23442159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
    Piña Y; Fusco MJ; Macaulay RJ; Walko CM; Peguero E; Evernden BR; Smalley KS; Forsyth P
    J Neurol; 2020 Mar; 267(3):783-790. PubMed ID: 31748891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular genetic alterations in pleomorphic xanthoastrocytoma.
    Paulus W; Lisle DK; Tonn JC; Wolf HK; Roggendorf W; Reeves SA; Louis DN
    Acta Neuropathol; 1996; 91(3):293-7. PubMed ID: 8834542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
    Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma.
    Lucas CG; Davidson CJ; Alashari M; Putnam AR; Whipple NS; Bruggers CS; Mendez JS; Cheshier SH; Walker JB; Ramani B; Cadwell CR; Sullivan DV; Lu R; Mirchia K; Van Ziffle J; Devine P; Goldschmidt E; Hervey-Jumper SL; Gupta N; Oberheim Bush NA; Raleigh DR; Bollen A; Tihan T; Pekmezci M; Solomon DA; Phillips JJ; Perry A
    J Neuropathol Exp Neurol; 2022 Jul; 81(8):650-657. PubMed ID: 35703914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
    J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
    Hatae R; Hata N; Suzuki SO; Yoshimoto K; Kuga D; Murata H; Akagi Y; Sangatsuda Y; Iwaki T; Mizoguchi M; Iihara K
    Neuropathology; 2017 Jun; 37(3):191-199. PubMed ID: 27792249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclin D1 expression in ganglioglioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma.
    Forest F; Dal Col P; Laville D; Court A; Rillardon M; Ramirez C; Rivoirard R; Stephan JL; Vassal F; Péoc'h M
    Exp Mol Pathol; 2021 Aug; 121():104652. PubMed ID: 34022185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.